Evolving guidelines for intravitreous injections

Lloyd P. Aiello, Alexander J. Brucker, Stanley Chang, Emmett T. Cunningham, Donald J. D'Amico, Harry W Flynn, Lisa R. Grillone, Steve Hutcherson, Jeffrey M. Liebmann, Terrence O'Brien, Ingrid U. Scott, Richard F. Spaide, Christopher Ta, Michael T. Trese

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

Intravitreous (IVT) injection is increasingly being incorporated into the management of ocular diseases. While only fomivirsen sodium (Vitravene™) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT injections indications is anticipated to grow on the basis of promising results from ongoing clinical studies. Despite the potential benefits that may be derived from intraocular injections of different agents, no guidelines have been published previously for IVT injection. The purpose of this document is to identify specific strategies for the delivery of IVT injection that may reduce risks and improve outcomes. Consensus was sought among a panel of investigators, surgeons experienced with this technique, and industry representatives. Objective evidence was sought for all guidelines, but consensus was accepted where evidence remains incomplete. In the absence of either evidence or consensus, the current manuscript identifies outstanding issues in need of further investigation. It is anticipated that more complete guidelines will evolve over time, potentially altering some of the guidelines included here, based on new applications of IVT injection, additional clinical experience, and results of clinical trials.

Original languageEnglish
JournalRetina
Volume24
Issue number5 SUPPL.
StatePublished - Oct 1 2004

Fingerprint

Guidelines
Injections
Intraocular Injections
Manuscripts
Eye Diseases
United States Food and Drug Administration
Industry
Research Personnel
Clinical Trials
fomivirsen

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Aiello, L. P., Brucker, A. J., Chang, S., Cunningham, E. T., D'Amico, D. J., Flynn, H. W., ... Trese, M. T. (2004). Evolving guidelines for intravitreous injections. Retina, 24(5 SUPPL.).

Evolving guidelines for intravitreous injections. / Aiello, Lloyd P.; Brucker, Alexander J.; Chang, Stanley; Cunningham, Emmett T.; D'Amico, Donald J.; Flynn, Harry W; Grillone, Lisa R.; Hutcherson, Steve; Liebmann, Jeffrey M.; O'Brien, Terrence; Scott, Ingrid U.; Spaide, Richard F.; Ta, Christopher; Trese, Michael T.

In: Retina, Vol. 24, No. 5 SUPPL., 01.10.2004.

Research output: Contribution to journalArticle

Aiello, LP, Brucker, AJ, Chang, S, Cunningham, ET, D'Amico, DJ, Flynn, HW, Grillone, LR, Hutcherson, S, Liebmann, JM, O'Brien, T, Scott, IU, Spaide, RF, Ta, C & Trese, MT 2004, 'Evolving guidelines for intravitreous injections', Retina, vol. 24, no. 5 SUPPL..
Aiello LP, Brucker AJ, Chang S, Cunningham ET, D'Amico DJ, Flynn HW et al. Evolving guidelines for intravitreous injections. Retina. 2004 Oct 1;24(5 SUPPL.).
Aiello, Lloyd P. ; Brucker, Alexander J. ; Chang, Stanley ; Cunningham, Emmett T. ; D'Amico, Donald J. ; Flynn, Harry W ; Grillone, Lisa R. ; Hutcherson, Steve ; Liebmann, Jeffrey M. ; O'Brien, Terrence ; Scott, Ingrid U. ; Spaide, Richard F. ; Ta, Christopher ; Trese, Michael T. / Evolving guidelines for intravitreous injections. In: Retina. 2004 ; Vol. 24, No. 5 SUPPL.
@article{b94567b8438447e8adea4b4a64fc2b6f,
title = "Evolving guidelines for intravitreous injections",
abstract = "Intravitreous (IVT) injection is increasingly being incorporated into the management of ocular diseases. While only fomivirsen sodium (Vitravene™) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT injections indications is anticipated to grow on the basis of promising results from ongoing clinical studies. Despite the potential benefits that may be derived from intraocular injections of different agents, no guidelines have been published previously for IVT injection. The purpose of this document is to identify specific strategies for the delivery of IVT injection that may reduce risks and improve outcomes. Consensus was sought among a panel of investigators, surgeons experienced with this technique, and industry representatives. Objective evidence was sought for all guidelines, but consensus was accepted where evidence remains incomplete. In the absence of either evidence or consensus, the current manuscript identifies outstanding issues in need of further investigation. It is anticipated that more complete guidelines will evolve over time, potentially altering some of the guidelines included here, based on new applications of IVT injection, additional clinical experience, and results of clinical trials.",
author = "Aiello, {Lloyd P.} and Brucker, {Alexander J.} and Stanley Chang and Cunningham, {Emmett T.} and D'Amico, {Donald J.} and Flynn, {Harry W} and Grillone, {Lisa R.} and Steve Hutcherson and Liebmann, {Jeffrey M.} and Terrence O'Brien and Scott, {Ingrid U.} and Spaide, {Richard F.} and Christopher Ta and Trese, {Michael T.}",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "24",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Evolving guidelines for intravitreous injections

AU - Aiello, Lloyd P.

AU - Brucker, Alexander J.

AU - Chang, Stanley

AU - Cunningham, Emmett T.

AU - D'Amico, Donald J.

AU - Flynn, Harry W

AU - Grillone, Lisa R.

AU - Hutcherson, Steve

AU - Liebmann, Jeffrey M.

AU - O'Brien, Terrence

AU - Scott, Ingrid U.

AU - Spaide, Richard F.

AU - Ta, Christopher

AU - Trese, Michael T.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Intravitreous (IVT) injection is increasingly being incorporated into the management of ocular diseases. While only fomivirsen sodium (Vitravene™) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT injections indications is anticipated to grow on the basis of promising results from ongoing clinical studies. Despite the potential benefits that may be derived from intraocular injections of different agents, no guidelines have been published previously for IVT injection. The purpose of this document is to identify specific strategies for the delivery of IVT injection that may reduce risks and improve outcomes. Consensus was sought among a panel of investigators, surgeons experienced with this technique, and industry representatives. Objective evidence was sought for all guidelines, but consensus was accepted where evidence remains incomplete. In the absence of either evidence or consensus, the current manuscript identifies outstanding issues in need of further investigation. It is anticipated that more complete guidelines will evolve over time, potentially altering some of the guidelines included here, based on new applications of IVT injection, additional clinical experience, and results of clinical trials.

AB - Intravitreous (IVT) injection is increasingly being incorporated into the management of ocular diseases. While only fomivirsen sodium (Vitravene™) is currently approved by the Food and Drug Administration as an IVT injection, the number of approved IVT injections indications is anticipated to grow on the basis of promising results from ongoing clinical studies. Despite the potential benefits that may be derived from intraocular injections of different agents, no guidelines have been published previously for IVT injection. The purpose of this document is to identify specific strategies for the delivery of IVT injection that may reduce risks and improve outcomes. Consensus was sought among a panel of investigators, surgeons experienced with this technique, and industry representatives. Objective evidence was sought for all guidelines, but consensus was accepted where evidence remains incomplete. In the absence of either evidence or consensus, the current manuscript identifies outstanding issues in need of further investigation. It is anticipated that more complete guidelines will evolve over time, potentially altering some of the guidelines included here, based on new applications of IVT injection, additional clinical experience, and results of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=6344263392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344263392&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Retina

JF - Retina

SN - 0275-004X

IS - 5 SUPPL.

ER -